NKGen Biotech (NKGN) shares rose by more than 24% in recent Wednesday trading after the company said the US Food and Drug Administration granted fast-track designation to troculeucel to treat moderate Alzheimer's disease.
The designation follows positive phase 1 trial results, which showed early signs of clinical benefit for patients treated with troculeucel, the company said.
NKGen is currently enrolling patients its phase 2a trial for moderate Alzheimer's disease patients and plans to release updated clinical data by the end 2025.
Price: 0.47, Change: +0.09, Percent Change: +24.01
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。